Burning Rock Biotech Ltd (BNR : NASDAQ)
Common Stock
$18.00
USD
+2.93 (19.40%)
Last updated: 2026-09-24
Follow BNR
BNR
Burning Rock Biotech Ltd
WealthAwesomePerformance
1 Day
+19.40%
1 Week
+33.14%
1 Month
+83.67%
YTD
+155.68%
Key Statistics
Market Cap
$189.83M
52W High
$41.72
52W Low
$6.79
P/E Ratio
-
50 Day MA
$10.56
200 Day MA
$17.18
Beta
1.39
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/24/2026 | $15.52 | $18.65 | $14.47 | $18.00 | $18.00 | 135,977 |
| 9/23/2026 | $16.44 | $16.45 | $14.35 | $15.07 | $15.07 | 24,099 |
| 9/22/2026 | $15.08 | $16.85 | $15.08 | $16.45 | $16.45 | 20,244 |
| 9/21/2026 | $14.47 | $15.43 | $14.47 | $14.73 | $14.73 | 9,972 |
| 9/18/2026 | $13.45 | $14.79 | $12.95 | $14.23 | $14.23 | 24,499 |
| 9/17/2026 | $12.68 | $13.90 | $12.68 | $13.52 | $13.52 | 5,247 |
| 9/16/2026 | $11.50 | $13.38 | $11.10 | $12.52 | $12.52 | 50,520 |
| 9/15/2026 | $11.72 | $11.86 | $11.38 | $11.68 | $11.68 | 8,228 |
| 9/14/2026 | $11.70 | $12.37 | $10.70 | $11.60 | $11.60 | 238,834 |
| 9/11/2026 | $11.70 | $12.58 | $11.21 | $12.28 | $12.28 | 50,958 |
Analyst Price Targets
Based on 1 analyst covering BNR · as of Sep 17, 2026
Wall Street analysts forecast BNR stock price to fall 77.6% over the next 12 months.
Consensus
Strong Buy5.00 / 5.00
Avg. Target
US$4.03
-77.6% Upside
Current Price
US$18.00
Last close
Analyst Breakdown (1 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BNR's historical volatility
30-Day Vol
118.1%
Annualized
90-Day Vol
103.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$21.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$19.10 | US$12.71 – US$28.71 |
| 60 trading days | US$20.28 | US$11.40 – US$36.07 |
| 90 trading days | US$21.52 | US$10.63 – US$43.58 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Financials
- Revenue (TTM)
- $500.64M
- EBITDA
- $-58.27M
- Profit Margin
- -13.59%
- ROE (TTM)
- -12.82%
- EPS (Diluted)
- -0.99
- Book Value
- 6.82
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About BNR.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| RPGL | Republic Power Group Limited Class A Ordinary Shares | $14.69 | +1363.23% |
| KITT | Nauticus Robotics Inc. | $2.93 | +459.21% |
| ZWZZT | NASDAQ TEST STOCK | $24.50 | +144.51% |
| SRZN | Surrozen Inc | $33.68 | +108.42% |
| GLND | Greenland Energy Company Common Stock | $5.35 | +83.85% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.65 | +80.62% |
| STAK | STAK Inc. Ordinary Shares | $1.44 | +53.19% |
| PFSA | Profusa, Inc. Common Stock | $3.03 | +47.80% |